



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Dr Pamela Sandu
NHS GREATER GLASGOW AND CLYDE
CLINICAL RESEARCH AND DEVELOPMENT CENTRAL OFFICE, DYKEBAR HOSPITAL,
WARD 11, GRAHAMSTON ROAD
PAISLEY
PA2 7DE
UNITED KINGDOM

31/03/2022

Dear Dr Pamela Sandu,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 24712/0060/001-0001
Eudract Number:	2021-006886-39
Product:	Noradrenaline (Norepinephrine), Plasma-Lyte® 148, Compound Sodium Lactate Solution for Infusion BP
Protocol number:	GN20AE342

NOTICE OF ACCEPTANCE OF AMENDED REQUEST

I am writing to inform you that the Licensing Authority accepts your amended request for a clinical trial authorisation (CTA), received on 31/01/2022.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

You are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed, changes made as part of your amended request may need to be notified to the Ethics Committee. If not already provided, please follow the guidance on our website on informing us of the registration status of your trial (where applicable).

You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:

o Import of IMPs from listed countries to GB:



<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

o Supply of IMPs to Northern Ireland:

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

o Substantial amendments to clinical trials:

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>

Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.

Yours sincerely,

Clinical Trials Unit
MHRA